According to preclinical studies, adagrasib effectively and consistently blocks KRAS-dependent signaling pathways with long-lasting effects, resulting in substantial tumor regression in 17 out of 26 (65%) KRAS-G12C-positive cell line- and patient-derived xenograft models (47). This evidence concerns the gene KRAS and neoplasm.